Diagnosis and treatment of invasive aspergillosis
AssigneesThe Brigham and Women's Hospital, Inc., The Charles Stark Draper Laboratory, Inc.
InventorsSophia Koo, Horatio R. Thomas, James Constantine Comolli, Preshious Rearden, Lindsey R. Baden, Francisco M. Marty
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.
Claims23
A method for diagnosing and treating a subject having invasive aspergillosis (IA), the method comprising:
- obtaining a sample comprising breath of the subject
- assaying the sample to detect the presence in the sample of one or both of beta-vatirenene and alpha-bergamotene;
- diagnosing the subject as having IA based on the presence of beta-vatirenene or alpha-bergamotene in the sample;
- and
- administering an antifungal treatment to the subject diagnosed as having IA.
A method of treating a subject who has invasive aspergillosis (IA), the method comprising:
- obtaining a sample comprising breath of the subject;
- assaying the sample to detect the presence in the sample of one or both of beta-vatirenene and alpha-bergamotene;
- and
- administering an antifungal treatment to the subject who has one or both of beta-vatirenene and alpha-bergamotene in the breath of the subject.
A method of monitoring efficacy of a treatment for invasive aspergillosis (IA) in a subject, the method comprising:
- assaying a first sample comprising breath from the subject to detect a first level of volatile organic compounds (VOCs) comprising one or both of beta-vatirenene and alpha-bergamotene;
- administering a treatment for IA to the subject;
- determining a second level of the VOCs in a second sample comprising breath from the subject obtained after administration of the treatment to the subject;
- and
- comparing the first and second levels of VOCs, wherein a decrease in the VOCs indicates that the treatment has been effective in treating the IA in the subject, and an increase or no change indicates that the treatment has not been effective in treating the IA in the subject.
A method for diagnosing and treating a subject having invasive aspergillosis (IA), the method comprising:
- obtaining a sample comprising headspace from a culture suspected of comprising Aspergillus isolated from the subject;
- assaying the sample to detect the presence in the sample of beta-vatirenene and alpha-bergamotene;
- diagnosing the subject as having IA based on the presence of beta-vatirenene and alpha-bergamotene in the sample;
- and
- administering an antifungal treatment to the subject diagnosed as having IA.
A method of treating a subject who has invasive aspergillosis (IA), the method comprising:
- obtaining a sample comprising headspace from a culture suspected of comprising Aspergillus isolated from the subject;
- assaying the sample to detect the presence in the sample of beta-vatirenene and alpha-bergamotene;
- and
- administering an antifungal treatment to the subject who has one or both of beta-vatirenene and alpha-bergamotene in the sample comprising headspace from the culture isolated from the subject.
A method of monitoring efficacy of a treatment for invasive aspergillosis (IA) in a subject, the method comprising:
- assaying a first sample comprising headspace from a culture suspected of comprising Aspergillus isolated from the subject to detect a first level of volatile organic compounds (VOCs) comprising beta-vatirenene and alpha-bergamotene;
- administering a treatment for IA to the subject;
- determining a second level of the VOCs in a second sample comprising headspace from a culture suspected of comprising Aspergillus isolated from the subject after administration of the treatment to the subject;
- and
- comparing the first and second levels of VOCs, wherein a decrease in the VOCs indicates that the treatment has been effective in treating the IA in the subject, and an increase or no change indicates that the treatment has not been effective in treating the IA in the subject.
Dependencies are inferred from the claim text.